No Data
Dyne Therapeutics To Present At J.P. Morgan Healthcare Conference; Webcast At 1:30 PM ET
Positive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory Advancements
Dyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock Recommendation
Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss
12 Health Care Stocks Moving In Friday's Pre-Market Session
Dyne Therapeutics Is Maintained at Buy by Chardan Capital